Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tinnitus Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Tinnitus Overview | 8 | 1 |
| Pipeline Products for Tinnitus Comparative Analysis | 9 | 1 |
| Tinnitus Therapeutics under Development by Companies | 10 | 1 |
| Tinnitus Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Tinnitus Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Tinnitus Products under Development by Companies | 15 | 1 |
| Tinnitus Products under Investigation by Universities/Institutes | 16 | 1 |
| Tinnitus Companies Involved in Therapeutics Development | 17 | 7 |
| AudioCure Pharma GmbH | 17 | 1 |
| Auris Medical Holding AG | 18 | 1 |
| Knopp Biosciences LLC | 19 | 1 |
| Merz Pharma GmbH &Co. KgaA | 20 | 1 |
| Otonomy, Inc. | 21 | 1 |
| SciFluor Life Sciences, LLC | 22 | 1 |
| Sound Pharmaceuticals, Inc. | 23 | 1 |
| Tinnitus Therapeutics Assessment | 24 | 8 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 1 |
| Drug Profiles | 32 | 20 |
| AM-102 Drug Profile | 32 | 1 |
| AUT-3 Drug Profile | 33 | 1 |
| Drug to Activate KCNQ for Tinnitus Drug Profile | 34 | 1 |
| esketamine hydrochloride Drug Profile | 35 | 5 |
| gacyclidine SR Drug Profile | 40 | 2 |
| neramexane mesylate Drug Profile | 42 | 2 |
| SF-0034 Drug Profile | 44 | 2 |
| Small Molecules for Tinnitus Drug Profile | 46 | 1 |
| Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus Drug Profile | 47 | 1 |
| Small Molecules to Inhibit TNF-Alpha for Tinnitus Drug Profile | 48 | 1 |
| SPI-1005 Drug Profile | 49 | 2 |
| SPI-3005 Drug Profile | 51 | 1 |
| Tinnitus Dormant Projects | 52 | 1 |
| Tinnitus Product Development Milestones | 53 | 8 |
| Featured News &Press Releases | 53 | 1 |
| Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus | 53 | 1 |
| Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million | 53 | 1 |
| Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus | 54 | 1 |
| Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus | 54 | 1 |
| Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus | 55 | 1 |
| Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City | 55 | 1 |
| Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus | 56 | 1 |
| Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311 | 56 | 1 |
| Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311 | 56 | 1 |
| Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio | 57 | 1 |
| Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience | 57 | 1 |
| Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals | 58 | 1 |
| Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus | 59 | 1 |
| Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City | 59 | 1 |
| Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101 | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |